August 31st, 2012
J&J to pay $181 mln to settle improper marketing claims
Johnson & Johnson said it has agreed to pay $181 million to settle consumer fraud claims by 36 U.S. states and the District of Columbia that it improperly marketed its Risperdal antipsychotic drug for unapproved uses.
The diversified healthcare company has also been targeted by federal authorities for separate but related allegations, including improperly promoting the drug for use in nursing homes.
J&J said it had already set aside funds to cover the civil settlement. The funds will be divided among the states participating in the settlement, announced on Thursday.
The company said the settlement was not an admission of wrongdoing.
“We have chosen this path to achieve a prompt and full resolution of these state claims,” Michael Yang, president of J&J’s Janssen Pharmaceuticals, said in a statement.